CVS Will Pay $315 Million Over Controlled Substance Prescriptions. Expect More Pharmacist Calls About Yours.
The Justice Department said on Oct. 13 that CVS will pay $315 million and agree to monitor prescribers suspected of illegal prescribing. CVS admits no wrongdoing, but the red flags the government listed are the prescriptions most likely to be questioned.
On Oct. 13, the Department of Justice announced that CVS Pharmacy Inc. and related entities will pay $315 million to resolve allegations that the chain filled invalid prescriptions for opioids and other controlled substances and then billed Medicare and other federal health care programs for many of them. The Justice Department release covers conduct alleged from Oct. 17, 2013, through Dec. 2, 2025.
The settlement resolves allegations only, and the department states that there has been no determination of liability. For prescribers, the stake is less in the dollar figure than in two other parts of the deal: the list of prescriptions the government says a pharmacist should have stopped, and a new obligation for a national pharmacy chain to evaluate prescribers it suspects of illegal prescribing.
What the government alleged
The United States filed its complaint on Dec. 13, 2024, in the U.S. District Court for the District of Rhode Island. It alleged that CVS knowingly filled controlled substance prescriptions that lacked a legitimate medical purpose, were not valid or were not issued in the usual course of professional practice. The examples the department gave were dangerous and excessive quantities of opioids, opioid prescriptions filled too early, "trinity" prescriptions combining an opioid, a benzodiazepine and a muscle relaxant, and prescriptions from what it called "pill mill" prescribers. It said pharmacists filled them despite clear red flags.
The complaint also blamed corporate performance metrics, incentive compensation and staffing policies, and alleged that CVS policies kept pharmacists from warning one another about certain problematic prescribers. The case began as a whistleblower suit under the False Claims Act filed by Hillary Estright, a former CVS employee, which the government took over. Her share of the recovery has not been determined.
What CVS says
CVS said in a statement that it strongly disagreed with the claims and that the settlement admits no wrongdoing, the Associated Press reported. The company said its pharmacists are trained "in the safe and appropriate use of all medications" and that it had put "best-in-class" programs in place to help them "make the best decisions on behalf of patients." When the suit was filed in 2024, CVS said pharmacists were being held to "vague, undefined, and ever-changing standards of practice" when filling opioid prescriptions, according to the AP.
A settlement is not a finding of fault. But the red flags it lists describe the prescriptions a pharmacist is most likely to question this year.
What CVS agreed to do
Beyond the payment, CVS signed a memorandum of agreement with the Drug Enforcement Administration covering its future dispensing. The company must set up a hotline for employees and the public to report suspected illegal dispensing, proactively monitor its pharmacies' dispensing patterns and establish a process to evaluate prescribers suspected of illegal prescribing. The release does not describe how that evaluation will work or what a prescriber would be told if flagged.
The AP noted that the federal government reached similar deals with Walgreens and Walmart in the past two years, and that opioid settlements with drugmakers, wholesalers and pharmacies now total more than $50 billion. The department tied this one to its new Task Force to Eliminate Fraud and National Fraud Enforcement Division, a signal that False Claims Act cases built on dispensing data will continue. Our coverage of the new CMS exclusion authority describes an enforcement tool aimed at physicians directly.
What it means in clinic
The agreement binds CVS, not other chains, and it does not change a prescriber's legal duties. But a pharmacy that has committed to monitoring prescribers is likely to question more of them, and a verification call or a delayed fill is the most likely result of a high-quantity opioid, an early refill or a benzodiazepine added to an opioid and a muscle relaxant.
The following are practical steps, not legal advice. Make sure the chart states the indication and your reasoning for any opioid, benzodiazepine and muscle relaxant combination, and for doses or early refills outside your usual pattern. Give staff a standing way to answer pharmacist verification calls the same day, so a legitimate prescription is not abandoned at the counter. And document your prescription drug monitoring program checks, since that record is what you will point to if a pharmacy, payer or regulator asks.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
